This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

This article was originally published here.